Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 152, Issue 3, 1995, Pages 897-905

  Wenzel, Sally E ^a   Trudeau, John B ^b   Kaminsky, David A ^b   Cohn, Judith ^b   Martin, Richard J ^b   Westcott, Jay Y ^b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ATROPINE; BRONCHODILATING AGENT; CODEINE; ISOPRENALINE; LEUKOTRIENE B4; LEUKOTRIENE E4; LIDOCAINE; LIPOXYGENASE INHIBITOR; METHACHOLINE; MIDAZOLAM; PEPTIDOLEUKOTRIENE; SALBUTAMOL; ZILEUTON;

ADULT; ARTICLE; ASTHMA; BRONCHOSCOPY; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FUNCTION TEST; LUNG LAVAGE; NEBULIZATION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SINGLE BLIND PROCEDURE;

EID: 0029123159     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.152.3.7663802     Document Type: Article

References (35)

1. Turner-Warwick, A. 1988. Epidemiology of nocturnal asthma. Am. J. Med. 85(Suppl. 1B):6-8.
2. Cochrane, G. M., and T. J. H. Clark. 1975. A survey of asthma mortality in patients between ages 35 and 64 in the Greater London hospitals in 1971. Thorax 30:300-305.
3. Martin, R. J., L. C. Cicutto, and R. D. Ballard. 1990. Factors related to the nocturnal worsening of asthma. Am. Rev. Respir. Dis. 141: 33-38.
4. Mohiuddin, A. A., and R. J. Martin. 1990. Circadian basis of the late asthmatic response. Am. Rev. Respir. Dis. 142:1153-1157.
5. Martin, R., L. C. Cicutto, H. R. Smith, R. D. Ballard, and S. J. Szefler. 1991. Airways inflammation in nocturnal asthma. Am. Rev. Respir. Dis. 143:351-357.
6. Beam, W. R., D. E. Weiner, and R. J. Martin. 1992. Timing of prednisone and alterations of airways inflammation in nocturnal asthma. Am. Rev. Respir. Dis. 146:1524-1530.
7. Henderson, W. R., Jr., 1987. Eicosanoids and lung inflammation. Am. Rev. Respir. Dis. 135:1176-1185.
8. Lewis, R. A., K. F. Austen, and R. J. Soberman. 1990. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323: 645-655.
9. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endo-bronchial allergen challenge. Am. Rev. Respir. Dis. 142:112-119.
10. Diaz, P., M. C. Gonzalez, F. R. Galleguillos, P. Ancic, O. Cromwell, D. Shepherd, S. R. Durham, G. J. Gleich, and A. B. Kay. 1989. Leukocytes and mediators in bronchoalveolar lavage during allergeninduced late-phase asthmatic reactions. Am. Rev. Respir. Dis. 139: 1383-1389.
11. 4 as a marker of nocturnal asthma (abstract). Am. Rev. Respir. Dis. 145:A16.
12. 1. J. Allergy Clin, Immunol. 94:870-881.
13. 4-receptor antagonist. N. Engl. J. Med. 323:1736-1739.
14. Israel, E., A. R. Fischer, M. A. Rosenberg, C. M. Lilly, J. C. Gallery, J. Shapiro, J. Cohn, P. Rubin, and J. M. Drazen. 1993. Pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am. Rev. Respir. Dis. 148:1447-1451.
15. Taylor, I. K., K. M. O'Shaughnessy, R. W. Fuller, and C. T. Dollery. 1991. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690-694.
16. Israel, E., P. Rubin, J. P. Kemp, J. Grossman, W, Pierson, S. C. Siegel, D. Tinkelman, J. J. Murray, W. Busse, A. T. Segal, J. Fish, H. B. Kaiser, D. Ledford, S. Wenzel, R. Rosenthal, J. Cohn, C. Lanni, H. Pearlman, P. Karahalios, and J. M. Drazen. 1993. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann. Intern. Med. 119:1059-1066.
17. ACCP-ATS Joint Committee on Pulmonary Nomenclature. 1975. Pulmonary terms and symbols: a report of the ACCP-ATS Joint Committee on Pulmonary Nomenclature. Chest 67:583-593.
18. Chai, H., R. S. Farr, L. A. Froelich, D. A. Mathison, J. A. McLean, R. R. Rosenthal, A. L. Sheffer, II, S. L. Spector, and R. G. Townley. 1975. Standardization of bronchial inhalation challenge procedures. J. Allergy Clin, Immunol. 56:323-327.
19. Bernstein, I. L., H. A. Boushey, R. M. Cherniack, J. N. Fink, J. D. Fulmer, E. J. Goetzl, R. A. Goldstein, S. S. Hurd, J. S. Ram, L. M. Lichtenstein, H. Y. Reynolds, R. M. Senior, R. A. Simon, P. Ward, and D. C. Zavala. 1985. Summary and recommendations of a workshop in the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in asthmatics. Am. Rev. Respir. Dis. 132:180-182.
20. Westcott, J. Y., K. Johnson, R. B. Thomas, and S. E. Wenzel. 1990. Measurement of peptidoleukotrienes in biologic fluids. J. Appl. Physiol. 68:2640-2648.
21. Pradelles, P., J. Grass, and J. Maclouf. 1985. Enzyme immuno-assays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal. Chem. 57:206-210.
22. Wenzel, S. E., J. Y. Westcott, H. R. Smith, and G. L. Larsen. 1989. Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups: an alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am. Rev. Respir. Dis. 139:450-457.
23. Granneman, G. R., R. A. Braeckman, and K. A. Erdman. 1995. Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high-performance liquid chromatography. Clin. Pharmacokinet. (In press)
24. Jones, B., and M. G. Kenward. 1989. Design and Analysis of Crossover Trials. Chapman and Hall, New York. 30-51.
25. Snedecor, G. W., and W. G. Cochran. 1989. Statistical Methods. Iowa State University Press, Ames. 333-366.
26. Awni, W. M., R. A. Braeckman, G. R. Granneman, G. Witt, and L.M. Dube. 1995. Pharmacokinetics and pharmacodynamics of zileuton after single and multiple 600-mg oral doses in healthy volunteers. Clin. Pharmacokinet. (In press)
27. Tagari, P., C. Brideau, C. Chan, R. Frenette, C. Black, and A. Ford-Hutchinson. 1993. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. Agents Actions 40: 62-71.
28. Tolino, M., G. Kane, M. Pollice, J. Cohn, R. Dworski, J. Sheller, J. Murray, and J. Fish. 1994. Sulfidopeptide leukotrienes in IgE-mediated early and late airway reactions in humans. Am. J. Respir. Crit. Care Med. 149:A531.
29. Kaever, V., and K. Resch. 1990. Eicosanoid synthesis in murine macrophages can be shifted from prostaglandins to leukotrienes but not vice versa by specific inhibitors of cyclooxygenase or 5-lipoxygenase activity. Adv. Prostaglandin Thromboxane Leukotriene Res. 21:169-172.
30. Wempe, J. B., E. P. Tammeling, G. H. Koeter, L. Hakansson, P. Venge, and D. S. Postma. 1992. Blood eosinophil numbers and activity during 24 hours effects of treatment with budesonide and bambuterol. J. Allergy Clin. Immun. 90:757-765.
31. Djukanovic, R., J. W. Wilson, K. M. Britten, S. J. Wilson, A. F. Walls, W. R. Roche, P. H. Howarth, and S. T. Holgate. 1992. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis. 145:669-774.
32. Diaz, P., F. R. Galleguillos, C. M. Gonzalez, D. F. A. Pantin, and A. B. Kay. 1984. Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins and complement. J. Allergy Clin. Immunol. 74:41-48.
33. 4 and granulocytic infiltration into asthmatic airways. Lancet 341:989-990.
34. Schade, U. F., M. Ernst, M. Reinke, and D. T. Wolter. 1989. Lipoxygenase inhibitors suppress formation of tumor necrosis factor in vitro and in vivo. Biochem. Biophys. Res. Commun. 159:748-754.
35. 4 to airway inflammation and the effect of antagonists. Ann. N. Y. Acad. Sci. 629:274-287.